SOLS
LONGCONGRESS SELLSolstice Advanced Matls Inc
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q1 2026 data — frozen, no longer refreshed.
News Summary
PositiveSolstice delivered strong Q1 and Q2 2026 results with revenue and earnings beats, raising full-year guidance amid robust demand from AI, semiconductors, and nuclear sectors. The company announced a transformational $14.5B acquisition of Element Solutions to create a $6.8B specialty chemicals leader, though this significantly increased leverage and prompted multiple analyst price target cuts.
Red flags
- •Q1 net income declined 37% year-over-year ($85M vs $134M) despite 10% revenue growth, signaling margin compression
- •Adjusted EBITDA margin compressed to 25.1% in Q1 from 27.9% YoY due to product mix, standalone costs, and R&D increases
- •Element Solutions acquisition materially increases leverage; company depends on debt financing in uncertain macro environment and successful synergy realization
- •Multiple analyst price target cuts following acquisition announcement (BMO $101→$90, Mizuho $95→$70, RBC $102→$82), suggesting investor concern about valuation and execution risk
- •Deal closing contingent on shareholder and regulatory approvals with execution risk through H1 2027
Funds Buying (3)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Coatue Management | Philippe Laffont | 1.7M | +1.7M | $126M | 0.4% | — | NEW |
| Point72 | Steve Cohen | 1.2M | +1.2M | $94M | 0.2% | — | NEW |
| Duquesne Family Office | Stanley Druckenmiller | 63K | +63K | $5M | 0.2% | — | NEW |
Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.
Portfolio Context
Where SOLS ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.
position #32 of this fund's book
- 29MASTEC INC$188M
- 30QUALCOMM INC$179M
- 31CARIS LIFE SCIENCES INC$176M
- 32SOLSTICE ADVANCED MATLS INC$126M
- 33C H ROBINSON WORLDWIDE IN$95M
- 34SPROUTS FMRS MKT INC$93M
- 35DOORDASH INC$83M
Values are quarter-end position sizes. Shown only for funds where SOLS ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| The Vanguard Group | SC 13G/A | 18.4M | 11.6% | 2026-01-30 | ↗ |
| BlackRock, Inc. | SC 13G | 16.5M | 10.4% | 2026-01-08 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.
Congressional Trading
| Member | Chamber | State | Type | Amount Range | Transaction Date | Filed | Src |
|---|---|---|---|---|---|---|---|
| Alan Armstrong | senate | — | SELL | $1,001 - $15,000 | 2026-03-24 | 2026-07-21 | ↗ |
Earlier trades (3) — dated outside this quarter's window, not counted in the badges
Periodic Transaction Reports filed under the STOCK Act. Amounts are disclosed as ranges, not exact dollar figures. Members often file weeks or months after trading, so trades are placed by transaction date: the badges above count trades dated since Jan 1, 2026.